{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:30:23Z","timestamp":1786681823157,"version":"build-2736575974"},"reference-count":78,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"crossref","award":["24-15-00334"],"award-info":[{"award-number":["24-15-00334"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"crossref"}]},{"award":["24-15-00334"],"award-info":[{"award-number":["24-15-00334"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Indolo[2,3-b]quinoxalines, along with their N-substituted derivatives, exhibit pronounced anticancer activity, although the mechanisms of their biological action may vary. Herein, a panel of sixty-five 6-(2-aminoethyl)-6H-indolo[2,3-b]quinoxaline derivatives comprising eight series with distinct amine moieties connected to the tetracyclic indoloquinoxaline core via a dimethylene linker was evaluated as drug-like candidates for kinase binding and cytotoxic activity. The ADME (Absorption, Distribution, Metabolism, and Excretion) properties of the compounds included in this set were preliminarily determined using the SwissADME tool. Analysis revealed that the library of quinoxaline derivatives largely complies with the drug-likeness rule for kinase-targeted compounds. As part of the biological screening, the compounds were initially tested on two cell lines MonoMac-6 and THP-1 (both derived from patients with acute monocytic leukemia) using sunitinib, a known antitumor agent acting as a multi-target receptor tyrosine kinase inhibitor, as a reference compound. Compound 3g, which demonstrated the highest activity in the cytotoxicity analysis (IC50 = 1.9 and 3.5 \u03bcM for the MonoMac-6 and THP-1 cell lines, respectively), was screened using the Eurofins DiscoverX scanEDGE panel, comprising 97 distinct kinases representing all known kinase families. Subsequently, the compound was tested using the Eurofins DiscoverX scanTK\u2122 panel, covering 135 distinct receptor and non-receptor tyrosine kinases. Based on initial screening results, compound 3g exhibits relatively high binding activity against fourteen tyrosine kinases, including TYK2, ZAP70, eight mutant forms of ABL1, two mutant forms of FLT3, and one mutant form of ALK, and demonstrates relatively high binding selectivity with respect to non-mutant tyrosine kinases (S-score: 0.024). Secondary screening of nine selected analogs of compound 3g led to the identification of compound 3h, which demonstrates relatively high binding affinity for FLT3 (D835V) (Kd = 0.41 \u03bcM). Molecular modeling suggested modes of binding interaction of the compounds 3h and 3g in the FLT3 (D835V) catalytic site. Our results demonstrate that 6-(2-aminoethyl)-6H-indolo[2,3-b]quinoxaline derivatives could be potential candidates for developing anticancer drugs.<\/jats:p>","DOI":"10.3390\/biom16081173","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:57:26Z","timestamp":1786521446000},"page":"1173","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["6-(2-Aminoethyl)-6H-indolo[2,3-b]quinoxalines as Promising Compounds Capable of Binding to FLT3 (D835V) Kinase"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-8110","authenticated-orcid":false,"given":"Igor A.","family":"Schepetkin","sequence":"first","affiliation":[{"name":"Department of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Uvarov","sequence":"additional","affiliation":[{"name":"Kizhner Research Center, Tomsk Polytechnic University, Tomsk 634050, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1301-0333","authenticated-orcid":false,"given":"Egor A.","family":"Evriinov","sequence":"additional","affiliation":[{"name":"Kizhner Research Center, Tomsk Polytechnic University, Tomsk 634050, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3022-4510","authenticated-orcid":false,"given":"Andrei I.","family":"Khlebnikov","sequence":"additional","affiliation":[{"name":"Kizhner Research Center, Tomsk Polytechnic University, Tomsk 634050, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lucaciu, R.L., Hangan, A.C., Sevastre, B., and Oprean, L.S. (2022). Metallo-drugs in cancer therapy: Past, present and future. Molecules, 27.","DOI":"10.3390\/molecules27196485"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e01173","DOI":"10.1002\/cbdv.202501173","article-title":"Exploring the anticancer properties of quinoxaline-based molecules: A systematic review","volume":"22","author":"Abdelall","year":"2025","journal-title":"Chem. Biodivers."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25204","DOI":"10.1039\/D2RA04498F","article-title":"Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: Synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents","volume":"12","author":"Ahmed","year":"2022","journal-title":"RSC Adv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1871520617666170710182405","article-title":"Design and discovery of novel quinoxaline derivatives as dual DNA intercalators and topoisomerase II inhibitors","volume":"18","author":"Eissa","year":"2018","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2174\/13895575113139990005","article-title":"6H-Indolo[2,3-b]quinoxalines: DNA and protein interacting saffold for parmacological ativities","volume":"13","author":"Moorthy","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0009-2797(01)00260-5","article-title":"DNA interaction and cytotoxicity of a new series of indolo[2,3-b]quinoxaline and pyridopyrazino[2,3-b]indole derivatives","volume":"138","author":"Arimondo","year":"2001","journal-title":"Chem. Bio. Interact."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1021\/jm970044r","article-title":"Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: A new class of putative topoisomerase inhibitors","volume":"40","author":"Deady","year":"1997","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1016\/j.tet.2006.09.017","article-title":"Intercalating nucleic acids (INAs) containing insertions of 6H-indolo[2,3-b]quinoxaline","volume":"62","author":"Wamberg","year":"2006","journal-title":"Tetrahedron"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ejmech.2009.12.014","article-title":"Synthesis, cytotoxicity, antiviral activity and interferon inducing ability of 6-(2-aminoethyl)-6H-indolo[2,3-b]quinoxalines","volume":"45","author":"Shibinskaya","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2478\/v10007-009-0040-9","article-title":"Synthesis, anticancer and cytostatic activity of some 6H-indolo[2,3-b]quinoxalines","volume":"59","author":"Karki","year":"2009","journal-title":"Acta Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7744","DOI":"10.1021\/jm800787b","article-title":"Interactions of antiviral indolo[2,3-b]quinoxaline derivatives with DNA","volume":"51","author":"Wilhelmsson","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41869","DOI":"10.1039\/C7RA08138C","article-title":"Synthesis, cytotoxic evaluation and DNA binding study of 9-fluoro-6H-indolo[2,3-b]quinoxaline derivatives","volume":"7","author":"Gu","year":"2017","journal-title":"RSC Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1021\/acs.jmedchem.3c00082","article-title":"Discovery and evaluation of 3-quinoxalin urea derivatives as potent, selective, and orally available ATM inhibitors combined with chemotherapy for the treatment of cancer via goal-oriented molecule generation and virtual screening","volume":"66","author":"Deng","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/(SICI)1521-4184(199811)331:11<352::AID-ARDP352>3.0.CO;2-2","article-title":"5-Substituted 2-bromoindolo[3,2-b]quinoxalines.: A class of potential antitumor agents with cdc25 phosphatase inhibitory properties","volume":"331","author":"Abadi","year":"1998","journal-title":"Arch. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gagic, Z., Ruzic, D., Djokovic, N., Djikic, T., and Nikolic, K. (2020). In silico methods for design of kinase inhibitors as anticancer drugs. Front. Chem., 7.","DOI":"10.3389\/fchem.2019.00873"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1016\/j.bmc.2009.02.054","article-title":"Structure-based virtual screening of Src kinase inhibitors","volume":"17","author":"Lee","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1039\/D4RA07556K","article-title":"Advances in pyrazolo 1,5-a pyrimidines: Synthesis and their role as protein kinase inhibitors in cancer treatment","volume":"15","author":"Iorkula","year":"2025","journal-title":"RSC Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1124\/mol.111.077446","article-title":"Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors","volume":"81","author":"Schepetkin","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12248","DOI":"10.1080\/07391102.2021.1969286","article-title":"FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: In silico studies","volume":"40","author":"Egbuna","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: Current status and future directions","volume":"16","author":"Baer","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","article-title":"Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies","volume":"9","author":"Verstovsek","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2019.240747","article-title":"Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia","volume":"106","author":"Burchert","year":"2021","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1021\/acs.jmedchem.8b01594","article-title":"Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia","volume":"62","author":"Liang","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.arcmed.2020.10.013","article-title":"FLT3-ITD and CD135 over-expression are frequent findings of poor survival in adult patients with acute leukemias","volume":"52","author":"Cardenas","year":"2021","journal-title":"Arch. Med. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5045\/br.2022.2022017","article-title":"FLT3 mutations in acute myeloid leukemia: A review focusing on clinically applicable drugs","volume":"57","author":"Ahn","year":"2022","journal-title":"Blood Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic relevance of FLT3-TKD mutations in AML: The combination matters\u2014An analysis of 3082 patients","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kennedy, V.E., and Smith, C.C. (2020). FLT3 mutations in acute myeloid leukemia: Key concepts and emerging controversies. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.612880"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2006-05-023804","article-title":"Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways","volume":"109","author":"Piloto","year":"2007","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3324\/haematol.2016.160101","article-title":"FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia","volume":"102","author":"Peschel","year":"2017","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1525-1578(10)60458-8","article-title":"Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay","volume":"5","author":"Murphy","year":"2003","journal-title":"J. Mol. Diagn."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12943-025-02455-y","article-title":"Novel molecular mechanisms of FLT3 deregulation: From the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia","volume":"24","author":"Salvesi","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1016\/j.bmcl.2017.06.035","article-title":"Virtual screening, synthesis and biological evaluation of DNA intercalating antiviral agents","volume":"27","author":"Klimenko","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1128\/MCB.25.9.3690-3703.2005","article-title":"Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases","volume":"25","author":"Markova","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.lab.2005.03.005","article-title":"Specific detection of FLT3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia","volume":"145","author":"Scholl","year":"2005","journal-title":"J. Lab. Clin. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e3114","DOI":"10.1038\/cddis.2017.458","article-title":"BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy","volume":"8","author":"Pereira","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_38","unstructured":"Burkert, U., and Allinger, N.L. (1982). Molecular Mechanics, American Chemical Society."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3720026","DOI":"10.1155\/2022\/3720026","article-title":"Exploring the resistance mechanisms of distal D835V mutation in FLT3 to inhibitors","volume":"2022","author":"Wang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1021\/jm051197e","article-title":"MolDock: A new technique for high-accuracy molecular docking","volume":"49","author":"Thomsen","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"044130","DOI":"10.1063\/5.0014475","article-title":"Scalable molecular dynamics on CPU and GPU architectures with NAMD","volume":"153","author":"Phillips","year":"2020","journal-title":"J. Chem. Phys."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acs.jcim.3c01648","article-title":"AMBERff at scale: Multimillion-atom simulations with AMBER force fields in NAMD","volume":"64","author":"Jones","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J. Chem. Theory Comput."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1021\/ct200133y","article-title":"Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values","volume":"7","author":"Sondergaard","year":"2011","journal-title":"J. Chem. Theory Comput."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/pro.3280","article-title":"Improvements to the APBS biomolecular solvation software suite","volume":"27","author":"Jurrus","year":"2018","journal-title":"Protein Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/jcc.21720","article-title":"Web servers and services for electrostatics calculations with APBS and PDB2PQR","volume":"32","author":"Unni","year":"2011","journal-title":"J. Comput. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"W522","DOI":"10.1093\/nar\/gkm276","article-title":"PDB2PQR: Expanding and upgrading automated preparation of biomolecular structures for molecular simulations","volume":"35","author":"Dolinsky","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"W665","DOI":"10.1093\/nar\/gkh381","article-title":"PDB2PQR: An automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations","volume":"32","author":"Dolinsky","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","article-title":"The AmberTools","volume":"63","author":"Case","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1021\/jz501780a","article-title":"Building water models: A different approach","volume":"5","author":"Izadi","year":"2014","journal-title":"J. Phys. Chem. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"114502","DOI":"10.1063\/5.0019056","article-title":"A fast and high-quality charge model for the next generation general AMBER force field","volume":"153","author":"He","year":"2020","journal-title":"J. Chem. Phys."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P","article-title":"Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method","volume":"21","author":"Jakalian","year":"2000","journal-title":"J. Comput. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1039\/D0MD00227E","article-title":"Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold","volume":"11","author":"Baillache","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"134627","DOI":"10.1016\/j.molstruc.2022.134627","article-title":"Cu-promoted synthesis of Indolo[2,3-b]quinoxaline-Mannich adducts via three-component reaction and their anti-proliferative evaluation on colorectal and ovarian cancer cells","volume":"1275","author":"Chowdhary","year":"2023","journal-title":"J. Mol. Struct."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/08927022.2013.809717","article-title":"Discovery of novel small-molecule Src kinase inhibitors via a kinase-focused druglikeness rule and structure-based virtual screening","volume":"40","author":"Li","year":"2014","journal-title":"Mol. Simul."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"104725","DOI":"10.1016\/j.phrs.2020.104725","article-title":"The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias","volume":"155","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ejso.2007.10.011","article-title":"Sunitinib in the management of gastrointestinal stromal tumours (GISTs)","volume":"34","author":"Hopkins","year":"2008","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Andr\u00e9s-Rodr\u00edguez, J., Gonz\u00e1lez-Montero, M.C., Garc\u00eda-Fern\u00e1ndez, N., Calvo-alvarez, E., P\u00e9rez-Pertejo, M.Y., Reguera-Torres, R.M., Bala\u00f1a-Fouce, R., and Garc\u00eda-Estrada, C. (2024). Free radical production induced by nitroimidazole compounds lead to cell death in Leishmania infantum amastigotes. Molecules, 29.","DOI":"10.3390\/molecules29174041"},{"key":"ref_59","first-page":"193","article-title":"Modeling of the anticancer action for radical derivatives of nitroazoles: Quantitative structure-activity relationship (QSAR) study","volume":"17","author":"Khlebnikov","year":"2002","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Olender, D., Zwawiak, J., and Zaprutko, L. (2018). Multidirectional efficacy of biologically active nitro compounds included in medicines. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020054"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"129759","DOI":"10.1016\/j.bbagen.2020.129759","article-title":"Protein kinases as targets for developing anticancer agents from marine organisms","volume":"1865","author":"Qiao","year":"2021","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Nishihara, S., Yamaoka, T., Ishikawa, F., Higuchi, K., Hasebe, Y., Manabe, R., Kishino, Y., Kusumoto, S., Ando, K., and Kuroda, Y. (2022). Mechanisms of EGFR-TKI-induced apoptosis and strategies targeting apoptosis in EGFR-mutated non-small cell lung cancer. Genes, 13.","DOI":"10.3390\/genes13122183"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Wang, T.D.Y., Pulkkinen, O.I., and Aittokallio, T. (2022). Target-specific compound selectivity for multi-target drug discovery and repurposing. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1003480"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"D31","DOI":"10.2741\/A767","article-title":"Abl: Mechanisms of regulation and activation","volume":"7","author":"Smith","year":"2002","journal-title":"Front. Biosci."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Leigh, R.S., Kaynak, B.L., Ruskoaho, H., and V\u00e4lim\u00e4ki, M.J. (2025). Development and comparison of single FLT3-inhibitors to dual FLT3\/TAF1-inhibitors as an anti-leukemic approach. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0320443"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1053\/j.seminhematol.2015.03.004","article-title":"FLT3 tyrosine kinase inhibition as a paradigm for targeted drug development in acute myeloid leukemia","volume":"52","author":"Grunwald","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: From basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1021\/cb500696t","article-title":"DFGmodel: Predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors","volume":"10","author":"Ung","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102247","DOI":"10.1016\/j.jbc.2022.102247","article-title":"Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors","volume":"298","author":"Arter","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tips.2026.01.009","article-title":"Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy","volume":"47","author":"Thapa","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: Homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA.py: An efficient program for end-state free energy calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J. Chem. Theory Comput."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"129305","DOI":"10.1016\/j.bmcl.2023.129305","article-title":"Design, synthesis, and biological evaluation of novel HDAC inhibitors with a 3-(benzazol-2-yl)quinoxaline framework","volume":"88","author":"Yang","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00044-026-03578-7","article-title":"Exploring new quinoxaline, quinoline, and naphthalene carboxamides as HDAC-targeted anticancer agents: Cytotoxicity, enzymatic HDAC evaluation, and in silico studies","volume":"35","author":"Jampahom","year":"2026","journal-title":"Med. Chem. Res."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:17:38Z","timestamp":1786681058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":78,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["biom16081173"],"URL":"https:\/\/doi.org\/10.3390\/biom16081173","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}